ABBV-066, Lutikizumab, ABBV-382, ABBV-066 / Risankizumab, ABBV-8736
M24-885
Phase 2 small_molecule active
Quick answer
ABBV-066, Lutikizumab, ABBV-382, ABBV-066 / Risankizumab, ABBV-8736 for Moderate to Severe Crohn’s Disease is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Moderate to Severe Crohn’s Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active